Published in J Virol on May 11, 2011
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Targeting the "cytokine storm" for therapeutic benefit. Clin Vaccine Immunol (2013) 1.17
Mechanism of RNA synthesis initiation by the vesicular stomatitis virus polymerase. EMBO J (2012) 1.12
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One (2013) 1.12
Arenavirus variations due to host-specific adaptation. Viruses (2013) 0.99
Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever. Antiviral Res (2012) 0.95
Favipiravir elicits antiviral mutagenesis during virus replication in vivo. Elife (2014) 0.93
Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology (2011) 0.89
The PI3K/Akt pathway contributes to arenavirus budding. J Virol (2012) 0.87
Characterization of synthetic Chikungunya viruses based on the consensus sequence of recent E1-226V isolates. PLoS One (2013) 0.84
Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol (2015) 0.83
Sodium hydrogen exchangers contribute to arenavirus cell entry. J Virol (2013) 0.82
Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses. Expert Opin Drug Discov (2012) 0.82
Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines. J Virol (2015) 0.82
Host cell factors as antiviral targets in arenavirus infection. Viruses (2012) 0.81
Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. J Virol (2013) 0.81
Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency. J Virol (2015) 0.81
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One (2013) 0.81
Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. J Infect Dis (2015) 0.79
Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses (2012) 0.79
Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol (2015) 0.77
Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication. J Virol (2015) 0.77
Mutagenesis-mediated decrease of pathogenicity as a feature of the mutant spectrum of a viral population. PLoS One (2012) 0.77
Changes in protein domains outside the catalytic site of the bacteriophage Qβ replicase reduce the mutagenic effect of 5-azacytidine. J Virol (2014) 0.75
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med (2008) 7.73
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73
Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med (2006) 5.42
RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A (2001) 5.21
Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog (2009) 4.88
Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol (1983) 4.45
Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A (1973) 4.36
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12
Virus dynamics and drug therapy. Proc Natl Acad Sci U S A (1997) 3.63
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J (1969) 2.76
Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol (2004) 2.58
Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis (1980) 2.38
Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol (1997) 2.36
Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci U S A (1994) 2.21
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol (2005) 2.00
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
International Commission for Protection Against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. Mutat Res (1994) 1.86
Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem (2001) 1.85
Ribavirin causes error catastrophe during Hantaan virus replication. J Virol (2003) 1.78
Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol (2005) 1.74
Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect (2002) 1.71
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Ribavirin--current status of a broad spectrum antiviral agent. Expert Opin Pharmacother (2001) 1.70
Genetic analysis of in vivo-selected viral variants causing chronic infection: importance of mutation in the L RNA segment of lymphocytic choriomeningitis virus. J Virol (1988) 1.62
Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62
Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci U S A (2002) 1.60
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58
Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol (2009) 1.58
Metabolism and antiviral activity of ribavirin. Virus Res (2005) 1.57
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis (2000) 1.52
Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol (2002) 1.52
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology (2003) 1.50
Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol (2001) 1.50
Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis (1997) 1.48
Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology (2003) 1.44
Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells. Biochem Pharmacol (1978) 1.36
Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res (1994) 1.33
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One (2008) 1.32
Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res (2008) 1.31
Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis (1984) 1.30
Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol (2005) 1.28
T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother (2010) 1.27
Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26
Phylogeny and evolution of old world arenaviruses. Virology (2006) 1.15
Lymphocytic choriomeningitis virus: an emerging obstetric pathogen? Am J Obstet Gynecol (2006) 1.11
Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol (2007) 1.10
Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology (2003) 1.10
Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction. Curr Top Microbiol Immunol (2002) 1.08
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
Properties of defective lymphocytic choriomeningitis virus. J Gen Virol (1972) 1.08
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology (2007) 1.07
Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother (1993) 1.07
Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat (2004) 1.07
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05
Treatment of lethal Pichinde virus infections in weanling LVG/Lak hamsters with ribavirin, ribamidine, selenazofurin, and ampligen. Antiviral Res (1993) 1.05
Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin Cancer Biol (2010) 1.05
Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology (2001) 1.04
Lymphocytic choriomeningitis virus: a neglected central nervous system pathogen. Clin Infect Dis (1996) 1.03
Arenavirus genetic diversity and its biological implications. Infect Genet Evol (2009) 1.03
Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology (2007) 1.02
No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology (2008) 1.01
Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol (2010) 1.01
The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol (2006) 1.00
Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol (2009) 1.00
Arenaviruses. II. The molecular pathogenesis of arenavirus infections. Introduction. Curr Top Microbiol Immunol (2002) 0.99
Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98
Homologous interference of lymphocytic choriomeningitis virus: detection and measurement of interference focus-forming units. J Virol (1976) 0.95
A comparison of biochemical and biological properties of standard and defective lymphocytic choriomeningitis virus. Bull World Health Organ (1975) 0.95
Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob Agents Chemother (1986) 0.92
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology (2005) 0.92
Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect Genet Evol (2005) 0.90
Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J Mol Biol (2008) 0.89
Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology (2007) 0.87
An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis. J Gen Virol (2009) 0.86
Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus. J Mol Biol (2011) 0.85
Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon-alpha, the immunomodulator CL246,738 and ribavirin. Antiviral Res (1989) 0.84
Ribavirin considerations in treatment optimization. Antivir Ther (2008) 0.83
Arenavirus diversity and evolution: quasispecies in vivo. Curr Top Microbiol Immunol (2006) 0.83
Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro. Virus Res (2008) 0.82
Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity. J Med Chem (2007) 0.80
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res Hum Retroviruses (2002) 0.78
Ribavirin induced differentiation of murine erythroleukemia cells. Mol Cell Biochem (1987) 0.77
Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet (2002) 4.42
Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem (2004) 2.48
Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J Virol (2002) 1.97
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol (2006) 1.80
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A (2006) 1.79
Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76
Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol (2003) 1.69
Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62
Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol (2004) 1.61
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci U S A (2013) 1.60
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58
Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol (2004) 1.58
Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. J Virol (2005) 1.57
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2003) 1.56
The structure of a protein primer-polymerase complex in the initiation of genome replication. EMBO J (2006) 1.54
Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A (2011) 1.51
Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J Virol (2002) 1.44
Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology (2003) 1.44
Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci U S A (2003) 1.41
Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest (2004) 1.39
Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A (2007) 1.37
Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol (2005) 1.36
High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. Gene (2005) 1.31
Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A (2003) 1.27
Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26
The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology (2011) 1.22
Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr Opin Struct Biol (2009) 1.22
Duration and fitness dependence of quasispecies memory. J Mol Biol (2002) 1.18
Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol (2007) 1.17
A reverse genetics system for Borna disease virus. J Gen Virol (2003) 1.16
Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε. J Virol (2012) 1.15
Mutant viral polymerase in the transition of virus to error catastrophe identifies a critical site for RNA binding. J Mol Biol (2005) 1.13
Use of alternative receptors different than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. Virology (2004) 1.11
Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses (2010) 1.11
The z protein of the new world arenavirus tacaribe virus has bona fide budding activity that does not depend on known late domain motifs. J Virol (2009) 1.10
Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology (2003) 1.10
Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J Virol (2007) 1.09
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One (2009) 1.08
Hidden virulence determinants in a viral quasispecies in vivo. J Virol (2008) 1.06
Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol (2010) 1.06
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05
Junín virus infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl Trop Dis (2012) 1.05
Molecular basis for a lack of correlation between viral fitness and cell killing capacity. PLoS Pathog (2007) 1.04
Viral genome segmentation can result from a trade-off between genetic content and particle stability. PLoS Genet (2011) 1.03
Arenavirus genetic diversity and its biological implications. Infect Genet Evol (2009) 1.03
Initial fitness recovery of HIV-1 is associated with quasispecies heterogeneity and can occur without modifications in the consensus sequence. PLoS One (2010) 1.02
No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology (2008) 1.01
Competition-colonization dynamics in an RNA virus. Proc Natl Acad Sci U S A (2010) 1.01
Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol (2010) 1.01
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol (2006) 1.00
Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling. Mol Immunol (2008) 0.99
Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10. PLoS One (2009) 0.98
Cells expressing the RING finger Z protein are resistant to arenavirus infection. J Virol (2004) 0.98
Quasispecies as a matter of fact: viruses and beyond. Virus Res (2011) 0.98
Resistance to extinction of low fitness virus subjected to plaque-to-plaque transfers: diversification by mutation clustering. J Mol Biol (2002) 0.98
Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98
A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology (2008) 0.97
Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine (2009) 0.97
Expansion of host-cell tropism of foot-and-mouth disease virus despite replication in a constant environment. J Gen Virol (2004) 0.97
RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2005) 0.97
Pathways to extinction: beyond the error threshold. Philos Trans R Soc Lond B Biol Sci (2010) 0.97
Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol (2002) 0.96
Altered central nervous system gene expression caused by congenitally acquired persistent infection with lymphocytic choriomeningitis virus. J Virol (2006) 0.96
Selective lymphocyte depletion during the early stage of the immune response to foot-and-mouth disease virus infection in swine. J Virol (2006) 0.96
Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One (2009) 0.94
Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell-specific manner. Cell Host Microbe (2011) 0.93
Guinea pig-adapted foot-and-mouth disease virus with altered receptor recognition can productively infect a natural host. J Virol (2007) 0.93
Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate. J Mol Biol (2008) 0.93
Role of the host cell's unfolded protein response in arenavirus infection. J Virol (2010) 0.93
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology (2005) 0.92
Adaptability costs in immune escape variants of vesicular stomatitis virus. Virus Res (2005) 0.92
Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev (2008) 0.92
Mutation hot spots in hepatitis B surface antigen in chronic carriers from Khoozestan province, southern of Iran. Iran J Allergy Asthma Immunol (2013) 0.92
Evolution of cell recognition by viruses: a source of biological novelty with medical implications. Adv Virus Res (2003) 0.92
Lethal mutagenesis of viruses. Curr Opin Virol (2011) 0.92
The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol (2012) 0.91
Identification of the Borna disease virus (BDV) proteins required for the formation of BDV-like particles. J Gen Virol (2005) 0.91
Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog (2006) 0.91
Fitness increase of memory genomes in a viral quasispecies. J Mol Biol (2004) 0.91
Evidence of the coevolution of antigenicity and host cell tropism of foot-and-mouth disease virus in vivo. J Virol (2003) 0.90
Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect Genet Evol (2005) 0.90
Modeling viral genome fitness evolution associated with serial bottleneck events: evidence of stationary states of fitness. J Virol (2002) 0.90
Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J Mol Biol (2007) 0.90
A methionine-rich domain mediates CRM1-dependent nuclear export activity of Borna disease virus phosphoprotein. J Virol (2006) 0.89
Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology (2011) 0.89